Opgen (OPGN)

Company Profile

OpGen, Inc. (Gaithersburg, MD, USA) is a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease. Along with subsidiaries, Curetis GmbH and Ares Genetics GmbH, OpGen is developing and commercializing molecular microbiology solutions helping to guide clinicians with more rapid and actionable information about life threatening infections to improve patient outcomes, and decrease the spread of infections caused by multidrug-resistant microorganisms, or MDROs. OpGen's product portfolio includes Unyvero, Acuitas®AMR Gene Panel and Acuitas® Lighthouse, and the ARES Technology Platform including ARESdb, using NGS technology and AI-powered bioinformatics solutions for antibiotic response prediction.

Company profile

Ticker

OPGN

Exchange

NASDAQ

Website

www.opgen.com

CEO

Oliver Schacht

Incorporated

Delaware

Location

Maryland

Fiscal year end

Dec 31

Sector

Health Care and Social Assistance > Medical Laboratories

Industry (SIC)

Services - Medical Laboratories

Quest Diagnostics • Laboratory Corp. Of America • Akumin • Radnet • Burning Rock Biotech • Guardant Health • Genomic Health • Invitae • Natera • Exact Sciences ...

SEC CIK

0001293818

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Plans of Reorganization

Indentures

Material Contracts & Credit Agreements

Subsidiaries Lists

Subsidiaries

AdvanDx, Inc. • OpGen A/S • Crystal GmbH • Curetis GmbH • Curetis USA • Ares Genetics GmbH ...

OPGN stock data

1M 1Y 5Y

Latest filings (excl ownership)

View all

Changes in Registrant's Certifying Accountant

20 Jan 23

8-K

OpGen Provides Preliminary Unaudited Revenue for FY 2022 and Business Update

18 Jan 23

8-K

OpGen Announces Pricing of $7.5 Million Public Offering

11 Jan 23

424B3

Prospectus supplement

11 Jan 23

EFFECT

Notice of effectiveness

9 Jan 23

S-1/A

IPO registration (amended)

5 Jan 23

8-K

OpGen Announced 1-for-20 Reverse Stock Split

4 Jan 23

S-1/A

IPO registration (amended)

30 Dec 22

8-K

OpGen Announces Positive Top Line Data from Clinical Trial for Unyvero Urinary Tract Infection Panel

13 Dec 22

Transcripts

View all

OPGN

Earnings call transcript

2022 Q3

11 Nov 22

OPGN

Earnings call transcript

2022 Q2

12 Aug 22

OPGN

Earnings call transcript

2022 Q1

13 May 22

OPGN

Earnings call transcript

2021 Q4

30 Mar 22

OPGN

Earnings call transcript

2021 Q3

12 Nov 21

OPGN

Earnings call transcript

2021 Q2

13 Aug 21

OPGN

Earnings call transcript

2021 Q1

13 May 21

OPGN

Earnings call transcript

2020 Q4

26 Mar 21

OPGN

Earnings call transcript

2020 Q3

11 Nov 20

OPGN

Earnings call transcript

2020 Q2

12 Aug 20

Latest ownership filings

View all

Prabhavathi Fernandes

Financial summary

Financial statements Chart OPGN financial data

Quarter (USD)	Sep 22	Jun 22	Mar 22	Dec 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 21	Dec 20	Dec 19	Dec 18
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	10.70 mm	10.70 mm	10.70 mm	10.70 mm	10.70 mm	10.70 mm
Cash burn (monthly)	2.11 mm	1.27 mm	4.70 mm	2.79 mm	1.58 mm	1.69 mm
Cash used (since last report)	8.91 mm	5.35 mm	19.85 mm	11.79 mm	6.69 mm	7.12 mm
Cash remaining	1.78 mm	5.35 mm	-9.15 mm	-1.10 mm	4.01 mm	3.57 mm
Runway (months of cash)	0.8	4.2	-1.9	-0.4	2.5	2.1

Beta Read what these cash burn values mean

Financial data from Opgen earnings reports.

Institutional ownership, Q3 2022

OPGN institutional ownership history Ownership history

16.1% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	21	25	-16.0%
Opened positions	1	4	-75.0%
Closed positions	5	7	-28.6%
Increased positions	7	6	+16.7%
Reduced positions	2	6	-66.7%

13F shares	Current	Prev Q	Change
Total value	2.47 mm	1.88 mm	+31.3%
Total shares	8.64 mm	3.45 mm	+150.1%
Total puts	0.00	0.00
Total calls	0.00	0.00
Total put/call ratio	–	–	–

Largest owners	Shares	Value	Change
Armistice Capital	5.30 mm	$1.52 mm	NEW
Vanguard	1.88 mm	$537.00 k	+39.8%
Geode Capital Management	362.68 k	$103.00 k	0.0%
BLK Blackrock	320.80 k	$92.00 k	0.0%
Arete Wealth Management	250.00 k	$72.00 k	+25.0%
Renaissance Technologies	117.50 k	$34.00 k	-83.0%
Citadel Advisors	100.77 k	$29.00 k	+571.0%
NTRS Northern Trust	69.79 k	$20.00 k	0.0%
UBS UBS Group AG - Registered Shares	68.04 k	$20.00 k	+1984.5%
BK Bank Of New York Mellon	40.48 k	$12.00 k	0.0%

Largest transactions	Shares	Bought/sold	Change
Armistice Capital	5.30 mm	+5.30 mm	NEW
Renaissance Technologies	117.50 k	-575.70 k	-83.0%
Vanguard	1.88 mm	+534.96 k	+39.8%
STT State Street	0.00	-129.20 k	EXIT
Two Sigma Securities	0.00	-120.96 k	EXIT
Citadel Advisors	100.77 k	+85.75 k	+571.0%
UBS UBS Group AG - Registered Shares	68.04 k	+64.77 k	+1984.5%
Arete Wealth Management	250.00 k	+50.00 k	+25.0%
Millennium Management	0.00	-24.23 k	EXIT
Two Sigma Advisers	33.00 k	-1.50 k	-4.3%

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

OPGN insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	#Shares	#Remaining
8 Nov 22	Schlaeppi Yvonne	Common Stock	Grant	Acquire A	No	No	30,000	30,000
9 Jun 22	Mario Crovetto	Common Stock	Grant	Acquire A	No	No	15,000	30,000
9 Jun 22	Elsey R Don	Common Stock	Grant	Acquire A	No	No	15,000	31,500
9 Jun 22	Prabhavathi Fernandes	Common Stock	Grant	Acquire A	No	No	15,000	30,000